• Immunome President and CEO Clay B. Siegall disclosed an open-market purchase of 25,450 common shares.
• Shares were bought at a weighted-average price of $19.67.
• Siegall reported direct ownership of 690,704 shares following the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001167496-26-000003), on March 31, 2026, and is solely responsible for the information contained therein.